Fund of the week: AN Venture Partners I

Overview and Investment Focus

AN Venture Partners (ANV) is not a conventional venture capital firm. It is a Tokyo and San Francisco-based fund built on a specific structural thesis: that Japan's academic biotech ecosystem is deeply underserved by institutional capital, and that bridging Japanese science to the U.S. startup model can produce globally competitive biotech companies.

Founded in 2022 in formal alliance with ARCH Venture Partners, one of the most influential life sciences VC firms in the world, ANV completed the final close of its debut fund, AN Venture Partners I, LP, at $200 million (approximately JPY 29 billion) in June 2025, making it one of the largest Japan-focused biotech venture capital funds raised to date and one of the largest first-time biotech VC funds closed in that year.

Investment Thesis: ANV's thesis is built on a clear geographic and structural arbitrage. Japan has world-class academic science, a deep pool of pharmaceutical expertise from its large domestic industry, and a government actively incentivising the commercialisation of life science research through programs such as AMED's Strengthening Program for the Pharmaceutical Startup Ecosystem. What it has historically lacked is a sophisticated venture infrastructure to translate that science into globally competitive biotech companies.

ANV targets this gap directly. The fund is modality-agnostic and disease-agnostic, investing across the full development spectrum from pre-proof-of-concept to advanced clinical stages, in any biotech or biotech-adjacent field where the science has the potential for significant clinical impact. It focuses primarily on science originating from Japan but retains the flexibility to invest globally. Crucially, ANV frequently takes an active role in company creation, working directly with academic founders at the earliest stages of licensing, spin-out formation, and company building rather than simply writing checks into externally-originated startups.

Background and Formation

ANV was formally established in 2022 by a group of experienced venture capitalists from Japan and the United States. The founding structure is notable for its formal alliance with ARCH Venture Partners, the Chicago-based firm best known for backing early Moderna, GRAIL, and dozens of other transformational biotech companies. This alliance gave ANV direct access to ARCH's institutional knowledge of company building and its network of scientific and industry relationships, while ANV itself brought deep Japan-specific expertise and government relationships that ARCH could not replicate independently.

The firm made its first investment in December 2023, and built out its portfolio progressively through 2024 and 2025. The fund held a first close well before the June 2025 final close, reflecting LP confidence in the team and thesis even before the portfolio had fully assembled. The AMED certification, secured in fiscal year 2024, was a significant validation milestone, formalising ANV's role as a recognised capital provider within Japan's national pharmaceutical startup support infrastructure and making ANV-backed companies eligible for AMED's direct financial support for non-clinical and early clinical trials.

The choice of dual headquarters reflects the firm's operating model. The Tokyo office is anchored in the GLOBAL LIFESCIENCE HUB at Nihonbashi Muromachi Mitsui Tower, positioning ANV within Japan's primary life science commercialisation hub. The San Francisco office provides proximity to the U.S. venture ecosystem, key service providers, and the clinical and regulatory infrastructure required to build globally competitive companies.

Strategic Differentiators

Japan-to-Global Translation as a Structural Advantage. ANV occupies a position that very few funds can credibly claim: genuine bilateral expertise across two of the world's most sophisticated pharmaceutical ecosystems. Japanese academic science, particularly in RNA biology, medicinal chemistry, and mitochondrial biology, is world-class, yet historically the commercialisation infrastructure to build it into globally competitive companies has been thin.

ANV's model addresses this by combining Japanese deal-sourcing with U.S. company-building playbooks. The ARCH alliance is operationally meaningful here, not merely nominal.

Active Company Creation, Not Passive Capital. ANV's investment approach explicitly includes company co-creation, not just investment. The firm works directly with academic founders at the licensing and spin-out stage, providing operational infrastructure, recruitment capability, and strategic direction from day one. This is a more labour-intensive model than conventional early-stage VC, but it gives ANV influence over company architecture from inception and allows it to import proven templates from the U.S. ecosystem into Japanese-origin ventures.

Government Integration as a Competitive Moat. ANV's AMED certification and working relationships with the Japanese Cabinet Office, MUFG, and multiple government agencies create deal flow channels and co-investment pathways that purely commercial funds cannot easily replicate. Japan's 2030 biotechnology leadership goal is a serious national policy priority, and ANV has positioned itself as a key private-sector implementation partner.

Science2Startup Japan as an Ecosystem and Deal Flow Engine. In November 2024, ANV brought the Science-to-Startup (S2S) event format from the U.S. to Japan for the first time, attracting nearly 200 Japanese researchers, academics, U.S. venture capitalists, and pharmaceutical industry representatives. This initiative creates proprietary deal flow, elevates ANV's brand among academic founders, and accelerates the commercialisation of research that would otherwise never reach institutional capital.

Portfolio

ANV had invested in at least seven companies as of the July 2025 final close, with three remaining in stealth mode at that time. The publicly disclosed portfolio spans RNA biology, gene writing, metabolic disease, rare cardiometabolic disorders, pulmonary hypertension, and uric acid metabolism, reflecting a deliberately broad therapeutic scope consistent with the fund's modality-agnostic mandate.

The portfolio's most significant validation to date is City Therapeutics. A next-generation siRNA company co-founded with intellectual property from two of the world's leading RNA scientists, City assembled a $135 million Series A in October 2024 and then announced strategic partnerships with Bausch + Lomb and Biogen within six months, with combined potential milestone payments exceeding $1.4 billion. For a fund that made its first investment in December 2023, this trajectory is exceptional. Crystalys Therapeutics represents a different but equally compelling playbook: bringing a clinically de-risked Japanese asset with existing regulatory approvals across Asian markets into global Phase 3 development, backed by a $205 million Series A from a blue-chip syndicate including Novo Holdings.

Fund Structure and Limited Partners

AN Venture Partners I, LP closed at $200 million (approximately JPY 29 billion) in June 2025 with more than 20 limited partners. Five anchor LPs were publicly named at close: Japan Investment Corporation, Shionogi & Co., Otsuka Pharmaceutical Co., MUFG Bank, and Sumitomo Mitsui Banking Corporation. The remaining 15+ investors have not been publicly identified. The composition of the anchor LP group is deliberate and meaningful, spanning sovereign capital, strategic pharma, and the two largest banking groups in Japan.

Japan Investment Corporation (JIC) is Japan's sovereign development fund, operating under the Ministry of Economy, Trade and Industry (METI). Established in 2018 from the reorganisation of the Innovation Network Corporation of Japan (INCJ), JIC invests across private equity, venture, and strategic industrial sectors with a mandate to strengthen Japan's international competitiveness and create a domestic virtuous cycle of risk capital.

Its venture arm, JIC Venture Growth Investments (JICVGI), established in July 2020, provides direct venture backing to growth-stage companies, while JIC itself takes LP positions in private funds aligned with national industrial priorities. JIC's participation in ANV Fund I is consistent with its stated thesis of catalysing private risk capital in areas where Japan trails the U.S. — biotech commercialisation being a primary example. JIC had already flagged biotechnology and life sciences as priority investment areas, and its LP role in ANV is effectively a policy investment as much as a financial one.

Shionogi & Co. is one of Japan's leading prescription drug companies, with a market capitalisation of approximately JPY 1.2 trillion and revenues dominated by its infectious disease franchise, including the HIV drug dolutegravir (via its stake in ViiV Healthcare, which it moved to expand to 21.7% in a $2.1 billion transaction in January 2026). Shionogi announced its investment agreement with ANV in December 2023, explicitly framing the LP commitment as a mechanism to advance its R&D pipeline, access the latest innovations in Japanese-origin science, and build internal know-how in early-stage biotech company creation by deploying personnel to ANV.

In April 2025, Shionogi established its own separate Corporate Venture Capital (CVC) group to pursue investments aligned with its 2030–2040 strategic goals, making the ANV LP position part of a broader move toward active external innovation engagement. The strategic dimension of Shionogi's participation is pronounced: any portfolio company developing assets in infectious disease, immunology, or adjacent areas would naturally have a direct potential licensing or co-development pathway through Shionogi.

Otsuka Pharmaceutical Co. announced its $30 million LP commitment to ANV in February 2024, making it one of the fund's larger disclosed check sizes relative to total fund size. Otsuka is a major Japanese pharma company best known for its CNS franchise (aripiprazole/Abilify), its global operations in 28 countries, and an annual revenue base of approximately $13 billion across pharmaceuticals and nutraceuticals.

Otsuka framed its investment explicitly: to support the commercialisation of Japanese science in the U.S. biotech ecosystem, receive investment dividends, gain access to early-stage innovation, and build internal expertise through ANV personnel secondments. Like Shionogi, Otsuka is not a passive financial LP. The commitment reflects a strategic decision to use fund positions as a window into the frontier of Japanese academic science commercialisation, particularly in areas adjacent to its existing pharmaceutical interests.

MUFG Bank (Mitsubishi UFJ Financial Group) and Sumitomo Mitsui Banking Corporation (SMBC) are the two largest banking groups in Japan and among the largest financial institutions in the world by assets. Their participation as LPs in ANV reflects a broader trend among Japanese megabanks to develop venture ecosystem relationships as part of their long-term corporate client strategy.

For MUFG and SMBC, ANV LP positions serve multiple functions: direct financial return, visibility into Japan's emerging biotech company formation pipeline, and relationship-building with the next generation of high-growth Japanese science companies that may require banking, treasury, and financial services as they scale globally.

The full LP roster of 20+ investors has not been publicly disclosed. Given the fund's Japan-government alignment, AMED certification, and relationships with the Japanese Cabinet Office, it is probable that the remaining LPs include additional Japanese institutional investors such as insurance companies, regional financial institutions, university endowments, or further pharmaceutical corporates. The balance between Japanese institutional capital and any potential non-Japanese LPs is not publicly known.

Leadership

Ken Horne, Managing Partner. Horne is the operational and strategic architect of ANV. An experienced healthcare investor, entrepreneur, and executive, he previously served as chairperson of RDiscovery, Remiges Ventures' company creation entity, where he helped start and invest in several companies including Capacity Bio and Typewriter Therapeutics. Before that, he co-founded or led Aline Aesthetics (acquired by Allergan), Symic Bio (acquired by Nordic Bio), and Teon Therapeutics, and was a founding member of TauTona Group, an early-stage life science VC backed by Stanford Management Company. He started his career at The Foundry, the medtech incubator.

Ari Nowacek, MD, PhD, MBA — Partner (simultaneously Partner, ARCH Venture Partners). Nowacek is the structural link between ANV and ARCH. A physician-scientist by training, he joined ARCH in 2015 and has been involved in the creation of companies including ROME Therapeutics, Walden Biosciences, and HiberCell. His dual role formalises the knowledge transfer between the two firms and gives ANV direct access to ARCH's company-building infrastructure and scientific network.

Takashi Futami, PhD, MBA — Partner. Futami leads ANV's Japan operations from Tokyo and brings a track record as a biotech investor in Japan, the U.S., and Europe, alongside company creation experience as a founder and executive. His role is essential to ANV's sourcing capability within Japanese academia and its domestic pharmaceutical industry relationships.

Jun Hashimoto — Partner. Hashimoto joined the partnership to strengthen the leadership team's financial, operational, and fundraising capabilities, based in Tokyo.

Portfolio Analysis

ANV's portfolio clusters reflect its geographic thesis clearly. The two most prominent clusters are advanced RNA modalities (City Therapeutics in siRNA, Typewriter Therapeutics in gene writing/transposon-based insertion) and metabolic and cardiovascular diseases with Japanese scientific origins (Crystalys in gout, Imbria in cardiometabolic, PAhR in pulmonary hypertension). This is not coincidental. Japan has exceptional academic strength in RNA science and a pharmaceutical industry with long-standing expertise in metabolic and cardiovascular drug development. ANV is systematically targeting the areas where Japanese science is deepest.

City Therapeutics is the portfolio's breakout asset to date. The company's scientific foundation, built on the intellectual property of two globally recognised RNA scientists, attracted tier-one pharma partnerships from Bausch + Lomb and Biogen within its first year of operation. The combined potential milestone value exceeding $1.4 billion, against a $135 million Series A, reflects the quality of the underlying platform. If the Biogen partnership in particular progresses to milestones, it would be a defining validation for both the company and the fund.

Crystalys Therapeutics represents a lower-risk, faster-to-value play. Dotinurad is already approved and commercialised in Japan and several Asian markets, meaning the principal risk for global Phase 3 is regulatory and commercial rather than scientific. The $205 million Series A co-led by Novo Holdings and supported by Perceptive Xontogeny and other specialist investors provides substantial capital for a focused registration strategy.

Typewriter Therapeutics and Capacity Bio are earlier-stage, higher-optionality bets. Typewriter's transposon-based gene writing platform is technically distinct from current CRISPR and base-editing approaches, and the AMED selection (up to $30 million) both validates the science and reduces early cash burn. Capacity Bio's mitophagy inducer platform is pre-clinical but addresses a large mechanistic space spanning neurodegeneration, rare genetic disorders, and autoimmune disease.

Strengths and Competitive Advantages

Privileged access to underserved Japanese academic IP. Japan has produced Nobel laureates in biology and chemistry with striking regularity and operates world-class university research programmes. Yet its biotech commercialisation rate relative to research output has been far lower than the U.S. or U.K. ANV occupies the front of the queue in a market where quality deal flow is structurally less competitive than in Boston or San Francisco.

ARCH alliance provides institutional knowledge at low cost. Building a venture firm from scratch typically requires decades of institutional learning. ANV has essentially licensed ARCH's company-building methodology and network by design, compressing the learning curve substantially. Ari Nowacek's presence as a simultaneous ARCH Partner makes this alliance operationally live rather than merely reputational.

LP base creates ecosystem integration. Having Shionogi and Otsuka as LPs creates a natural commercial pathway for portfolio companies seeking Japanese pharmaceutical partnerships, co-development, or licensing. Few global biotech VCs can offer their portfolio companies direct access to the boards of major Japanese pharma groups at fund inception.

Government alignment generates durable deal flow. ANV's AMED certification, government agency relationships, and Science2Startup Japan initiative create proprietary sourcing channels that are inherently difficult for new entrants to replicate. These relationships take years to build and have institutional depth beyond any individual.

City Therapeutics validates the Japan-origin thesis early. The speed with which City assembled $135 million in institutional capital and then secured two major pharma partnerships provides early-stage proof-of-concept for ANV's model. For a fund that made its first investment in December 2023, having a portfolio company announce billion-dollar partnership frameworks within 18 months is a strong signal.

Risks, Challenges, and Vulnerabilities

Small portfolio, limited diversification. At seven known investments from a $200 million fund, ANV is running a concentrated book. If City Therapeutics or Crystalys encounter clinical or regulatory setbacks, fund-level outcomes will be substantially affected. The three stealth companies add opacity to this assessment.

Japan ecosystem development risk. ANV's mission is partly to build the infrastructure it needs — the Science2Startup events, the AMED relationships, the academic networks — while simultaneously deploying fund capital. Ecosystem building takes time and does not always correlate with investment returns within a typical fund life.

Currency exposure. A dollar-denominated fund investing in science originating from Japan, with LPs including major Japanese financial institutions, has non-trivial yen-dollar exposure. The fund structure and hedging approach have not been publicly disclosed.

First-time fund manager risk. Despite the team's experience, AN Venture Partners I is the firm's debut institutional fund. LP track records, management fees, carried interest structures, and governance practices are all being established for the first time. First-time managers face higher scrutiny in subsequent fundraises, and the team will need to demonstrate DPI alongside TVPI to secure strong LP re-commitment for Fund II.

Japanese biotech commercialisation risk. The hypothesis that Japan is an untapped source of globally competitive biotech science is plausible and well-argued, but it has not been proven at scale. Prior attempts to build Japan-focused biotech funds produced mixed results. ANV's structural differentiation (ARCH alliance, AMED certification, active company creation) addresses this historically, but execution risk remains real.

Company creation is operationally intensive. Taking an active role in founding companies alongside academic scientists is a high-touch, resource-intensive model. With a relatively lean team for a $200 million fund, ANV will need to prioritise carefully and manage the operational demands of early-stage company building across multiple simultaneous ventures.

Recent Developments (2024–2026)

ANV's most active period has been the twelve months following the fund's final close. In July 2025, the firm announced the $14 million seed financing of PAhR Therapeutics alongside RA Capital Management and UTEC. In September 2025, Crystalys Therapeutics launched with a $205 million Series A co-led by Novo Holdings, representing the largest financing round in ANV's portfolio to date. The fund's most recent disclosed investment was a follow-on into Imbria Pharmaceuticals in December 2025, as Imbria advances ninerafaxstat toward Phase 2b.

On the ecosystem side, ANV's Science2Startup Japan programme continued to expand following the inaugural November 2024 event, deepening the firm's relationships with Japanese academic institutions and government agencies. Typewriter Therapeutics hired a Head of R&D Japan in early 2025, signalling operational maturation of that programme. City Therapeutics' Biogen partnership, announced May 2025 with up to $1 billion in potential milestones, remains the single most significant external validation event in the portfolio.

As of March 2026, the fund is believed to be substantially committed, with capital concentrated across the seven disclosed portfolio companies and the remaining stealth investments. A Fund II process has not been publicly announced.

Conclusion

AN Venture Partners I is one of the more clearly differentiated debut biotech funds to have closed in recent years. Its structural thesis — that Japanese academic science is a systematically underserved source of globally competitive biotech IP — is specific, testable, and supported by early evidence from City Therapeutics and Crystalys Therapeutics. The ARCH Venture Partners alliance provides institutional credibility and a meaningful operational bridge between Japanese scientific origination and U.S.-style company building. The LP base, anchored by Japan Investment Corporation, Shionogi, Otsuka, MUFG, and SMBC, reflects both financial alignment and strategic integration with Japan's national biotechnology agenda.

The open questions at this stage of the fund's life are primarily ones of execution. Can the active company-creation model scale across a portfolio without over-stretching a relatively lean team? Will Japanese-origin science generate U.S.-level clinical outcomes at the pace required for fund-level returns within a ten-to-twelve year fund life? And can ANV repeat the City Therapeutics outcome — a Japanese-IP-anchored company attracting global tier-one pharma partnerships — across enough portfolio companies to justify the model at scale?

The early portfolio construction suggests ANV understands both the opportunity and the difficulty. City Therapeutics' trajectory is exceptional by any standard. Crystalys offers a lower-risk, de-risked path to value. Typewriter and Capacity Bio represent the higher-optionality science bets that are essential for fund-level outperformance. If the three stealth companies are of comparable quality, this is a portfolio that warrants close attention.

All information in this article was accurate as of March 2026 and is derived from publicly available sources including company press releases, regulatory announcements, and financial news reporting. Information may have changed since publication. This content is for informational purposes only and does not constitute investment, legal, or financial advice. The author is not a lawyer or financial adviser.